Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of September 2025, with a specific reporting date of September 5, 2025. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation awards rather than operational financial performance.
Material Changes and Transactions
The filing details the grant of conditional share awards to two PDMRs on September 4, 2025, outside of a trading venue. These grants were made at a price of Nil.
- Carl Haney (Chief R&D Officer): Received 641,096 Ordinary Shares under the Performance Share Plan (Interim) and 192,571 Ordinary Shares under the Share Value Plan (Buyout), totaling 833,667 shares.
- Nathalie Gerschtein (President North America): Received 244,400 American Depositary Shares (ADS) under the Performance Share Plan (Interim) and 405,911 ADS under the Share Value Plan (Buyout), totaling 650,311 ADS.
Guidance, Outlook, and Risks
The Performance Share Plan (Interim) awards are subject to continued employment and performance conditions over a period ending December 31, 2027, with vesting scheduled for March 2028. Specific performance targets were previously disclosed in the 2024 Annual Report and Form 20-F. The Share Value Plan (Buyout) awards are subject only to continued employment. All awards adhere to Haleon's Directors' Remuneration Policy and include malus and clawback provisions. The filing does not contain new guidance, outlook, or specific risk factors beyond the standard conditions of the equity plans.
Key Facts for Investor Verification
- Verify the specific performance targets for the 2027 vesting period referenced in the 2024 Annual Report.
- Confirm the total number of shares/ADS outstanding post-grant to assess dilution impact.
- Review the Directors' Remuneration Policy for details on malus and clawback triggers.
- Note that these transactions were grants of conditional awards, not open market purchases or sales.